Orlistat-induced weight loss results in amelioration in several comorbidities including obesity-related dyslipidemia. The aim of the present study was to characterize the changes in the blood plasma metabolic profile ...Orlistat-induced weight loss results in amelioration in several comorbidities including obesity-related dyslipidemia. The aim of the present study was to characterize the changes in the blood plasma metabolic profile from overweight women treated with Orlistat, a lipase inhibitor. A metabonomic approach employing LHNMR was applied to the access metabolic profile in lean and overweight women after a 120 day treatment with 120 mg of Orlistat three times daily. Twenty overweight women （BMI： 32.8 ± 2.9 kg/m2） were evaluated before and after Orlistat treatment and seven normal weight women （BMh 21.8 ± 1.4 kg/m2） were taken as control. After 120 days of treatment with Orlistat, no significant weight changes were observed. However, Orlistat-induced metabolic changes in overweight subjects decreased the profile differences between lean and obese individuals, independent of weight loss. These were associated to decreasing levels of lactate and calcium. Higher levels of lactate, alanine and lipids from overweight subjects were detected in comparison to lean individuals. These results show that a lipase inhibitor shifts the metabolic profile of overweight subjects towards normality, independent of weight loss.展开更多
文摘Orlistat-induced weight loss results in amelioration in several comorbidities including obesity-related dyslipidemia. The aim of the present study was to characterize the changes in the blood plasma metabolic profile from overweight women treated with Orlistat, a lipase inhibitor. A metabonomic approach employing LHNMR was applied to the access metabolic profile in lean and overweight women after a 120 day treatment with 120 mg of Orlistat three times daily. Twenty overweight women （BMI： 32.8 ± 2.9 kg/m2） were evaluated before and after Orlistat treatment and seven normal weight women （BMh 21.8 ± 1.4 kg/m2） were taken as control. After 120 days of treatment with Orlistat, no significant weight changes were observed. However, Orlistat-induced metabolic changes in overweight subjects decreased the profile differences between lean and obese individuals, independent of weight loss. These were associated to decreasing levels of lactate and calcium. Higher levels of lactate, alanine and lipids from overweight subjects were detected in comparison to lean individuals. These results show that a lipase inhibitor shifts the metabolic profile of overweight subjects towards normality, independent of weight loss.
